Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome

<div>Mean daily defined doses (DDDs) of gabapentinoids (a) and tricyclic antidepressants (TCA) (b) and also percent of the maximum dose of serotonin-norepinephrine reuptake inhibitors (SNRIs) (c) 2 y before and 1 y after disability pension (DP) in persistent spinal pain syndrome patients with spinal cord stimulation at KUH. The mean DDD was calculated as the average of total purchased drugs during the specific six-month period (months: 0–6; 6–12; 12–18; 18–24 before and 0–6; 6–12 after DP). For SNRI drugs, the DDD/day of drug use was related to the maximum daily dose of the same drug. The maximum dose was 120 mg/day for duloxetine and 375 mg/day for venlafaxine.</div>

Pain Research and Management

fig3

Figure 3

Figure 3: Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome 

Figure 3 | Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome 